Related Experiment Video
Updated: Aug 2, 2026
07:32
Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019
Identification of novel mdm2 binding peptides by phage display
V Böttger1, A Böttger, S F Howard
1Cancer Research Campaign Laboratories, University of Dundee, Scotland, UK.
Oncogene
|November 21, 1996
Summary
Researchers discovered novel peptides that strongly inhibit the mdm2-p53 interaction, a key target in cancer drug development. These peptides show potential as new anti-cancer therapeutics by blocking this crucial protein binding.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- The oncogene mdm2/hdm2 protein inactivates the tumor suppressor p53, a mechanism implicated in various cancers.
- The mdm2-p53 interaction is a significant target for developing novel anti-cancer drugs.
Purpose of the Study:
- To identify high-affinity ligands that disrupt the mdm2-p53 binding interaction.
- To explore the potential of phage display libraries for discovering peptide-based therapeutic leads.
Main Methods:
- Screening of phage display peptide libraries to identify mdm2-binding phage.
- Characterization of peptide sequences and their homology to the p53 binding site.
- Inhibition assays (ELISA) to quantify the potency of synthetic peptides.
Main Results:
- Identified 12mer and 15mer peptides with strong binding affinity for hdm2.
- Confirmed the crucial role of the p53 18TFSDLW23 region and extended contact to L26.
- Phage-derived synthetic peptides demonstrated up to 100-fold greater inhibition of p53-mdm2 interaction compared to wild-type p53 peptides.
Conclusions:
- Phage display is a powerful tool for discovering peptide inhibitors of protein-protein interactions.
- Novel peptide ligands can effectively inhibit the mdm2-p53 interaction, offering a promising avenue for cancer therapy.
- These findings highlight the therapeutic potential of targeting protein-protein interactions with peptide-based drugs.
